Evidence map›Paper›PMID 39076142›Full record

ArticleRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2024

Invasive group A Streptococcus infection (Streptococcus pyogenes): Current situation in Spain.

M C Martín-Delgado, P De Lucas Ramos, A García-Botella, R Cantón, A García-Lledó, T Hernández-Sampelayo, J Gómez-Pavón, J González Del Castillo, F J Martín Sánchez, M Martínez-Sellés and 13 more

Abstract read
In one paragraph

Article in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Severe invasiveJournal of intensive medicine · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

M C Martín-Delgado
P De Lucas Ramos
A García-Botella
R Cantón
A García-Lledó
T Hernández-Sampelayo
J Gómez-Pavón
J González Del Castillo
F J Martín Sánchez
M Martínez-Sellés
J M Molero García
S Moreno Guillén
F J Rodríguez-Artalejo
J Ruiz-Galiana
A Burillo
P Muñoz
C Calvo Rey
M Catalán-González
E Cendejas-Bueno
V Halperin-Benito
R Recio
C Viñuela-Benítez
E BouzaEmilio Bouza. Servicio de Microbiología Clínica y Enfermedades Infecciosas. Hospital General Universitario Gregorio Marañón, Universidad Complutense. CIBER de Enfermedades Respiratorias (CIBERES). Madrid. Spain. emilio.bouza@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Group A ß-hemolytic Streptococcus (S. pyogenes), also known as GAS, is a Gram-positive bacterium. It can be easily identified in the microbiology laboratory by its ability to hemolyse blood in culture media. This bacterium is highly virulent due to its production of enzymes and toxins, and its ability to cause immunologically mediated diseases such as rheumatic fever and post-streptococcal glomerulonephritis. GAS is the primary cause of bacterial pharyngotonsillitis, although it is typically a benign and non-invasive disease. However, it also has the potential to cause severe skin and soft tissue infections, necrotising fasciitis, bacteraemia and endocarditis, pneumonia and empyema, and streptococcal toxic shock syndrome, without any age or predisposition limits. The term invasive GAS disease (iGAS) is used to refer to this group of conditions. In more developed countries, iGAS disease has declined thanks to improved hygiene and the availability of antibiotics. For example, rheumatic fever has practically disappeared in countries such as Spain. However, recent data suggests a potential increase in some iGAS diseases, although the accuracy of this data is not consistent. Because of this, the COVID and Emerging Pathogens Committee of the Illustrious Official College of Physicians of Madrid (ICOMEM) has posed several questions about invasive GAS infection, especially its current situation in Spain. The committee has enlisted the help of several experts in the field to answer these questions. The following lines contain the answers that we have collaboratively produced, aiming to assist not only the members of ICOMEM but also anyone interested in this topic.

Indexed as

Streptococcal InfectionsStreptococcus pyogenesAnti-Bacterial AgentsHumansSpainAnti-Bacterial Agentsbacteraemiaempyemaendocarditisexplosive pleuritisglomerulonephritisgroup A streptococcusnecrotising fasciitispharyngotonsillitispneumoniarheumatic feverskin and soft tissue infectionstreptococcal toxic shock syndromeStreptococcus pyogenes

Identifiers

PMID39076142
PMCPMC11578432

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.